Plain-English translation of NCT07563881 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it can help adults with focal seizures (seizures that start in one area of the brain) better control their condition. About 333 people will receive either a higher dose of the medication, a medium dose, or a placebo (a pill with no active ingredient) to compare how well each works. After the main study ends, participants can choose to continue in a longer-term safety study to see how the treatment works over time.
Many people with focal epilepsy still have seizures even while taking one or more current seizure medications. This trial is testing whether this new treatment option could help people who need better seizure control.
You likely qualify if…
You likely don't qualify if…
You will take a daily tablet by mouth for several weeks or months. During the study, you'll visit the clinic for check-ups and continue tracking your seizures in a daily log using a phone or tablet. You'll have an equal chance of receiving the high-dose medication, medium-dose medication, or placebo (you and the researchers won't know which one you're getting). After the main study ends, you can choose to join a longer-term follow-up study to continue the treatment, or you'll have an 8-week follow-up period to monitor how you do.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States